Breaking News Instant updates and real-time market news.

CBS

CBS

$56.79

0.94 (1.68%)

, ED

Consolidated Edison

$76.55

0.66 (0.87%)

13:59
02/15/18
02/15
13:59
02/15/18
13:59

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Consolidated Edison (ED), consensus 77c... CBS (CBS), consensus $1.14... Arista Networks (ANET), consensus $1.41... SS&C Technologies (SSNC), consensus 53c... Cognex (CGNX), consensus 25c... LogMeIn (LOGM), consensus $1.17... Flowserve (FLS), consensus 51c... MuleSoft (MULE), consensus (12c)... Allscripts Healthcare Solutions (MDRX), consensus 18c... TrueCar (TRUE), consensus 0c.

CBS

CBS

$56.79

0.94 (1.68%)

ED

Consolidated Edison

$76.55

0.66 (0.87%)

ANET

Arista Networks

$303.29

1.17 (0.39%)

SSNC

SS&C

$49.76

0.75 (1.53%)

CGNX

Cognex

$58.05

2.88 (5.22%)

LOGM

LogMeln

$130.20

4.25 (3.37%)

FLS

Flowserve

$42.72

0.53 (1.26%)

MULE

MuleSoft

$26.02

0.5975 (2.35%)

MDRX

Allscripts

$14.45

0.29 (2.05%)

TRUE

TrueCar

$11.25

0.275 (2.51%)

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 15

    Feb

  • 16

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 29

    Mar

  • 30

    May

CBS CBS
$56.79

0.94 (1.68%)

02/12/18
BMOC
02/12/18
NO CHANGE
Target $34
BMOC
Market Perform
Viacom price target raised to $34 from $27 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Viacom (VIAB) to $34, saying he remains "impressed" by the management's turnaround at the company, as seen in its better affiliate fee outlook, upcoming "direct to consumer" product launch, acquisitions of Vidcon and WHOSAY, and stronger international growth. The analyst also keeps his Market Perform rating, citing limited visibility around a potential CBS (CBS) deal as well as the company's asset mix remaining challenging.
02/09/18
RBCM
02/09/18
UPGRADE
Target $35
RBCM
Sector Perform
Viacom upgraded to Sector Perform at RBC on increasing likelihood of CBS deal
As reported earlier, RBC Capital analyst Steven Cahall upgraded Viacom (VIAB) to Sector Perform and raised his price target to $35 from $23, saying the combination with CBS (CBS) is increasingly likely. Cahall says he has been negative on Viacom for about two years based on the view of its networks being more at risk than peers from a "deteriorating ecosystem". Now that the merger with CBS is back on "likely in the coming months", the analyst contends, the transaction multiples near market prices would justify a more constructive view.
01/30/18
DBAB
01/30/18
NO CHANGE
Target $90
DBAB
Buy
Standalone or merger, Deutsche sees CBS shares going higher
Deutsche Bank analyst Bryan Kraft laid out his analysis for CBS (CBS) shares under different merger scenarios. The analyst values the stock at $90 in 12 months should CBS remain independent. In a merger with Viacom (VIAB), the analyst's pro forma 12-month valuation has the stock also worth $90. Kraft also analyzed a three-way merger transaction which combines CBS, Viacom and Lionsgate (LGF.A). Under this scenario, the analyst values CBS shares at $96 on a 12-month basis. Kraft has a Buy rating on CBS with a $90 price target.
02/12/18
BRRR
02/12/18
NO CHANGE
BRRR
Potential reunion with CBS looms over Viacom fundamentals, says Barrington
Barrington analyst James Goss noted that Viacom (VIAB), which reported Q1 earnings last Thursday, beat the firm's EPS estimate, but fell 4% short of its revenue estimate, mainly due to a larger-than-expected decline in the revenue rate for Paramount. Godd reiterated a Market Perform rating on Viacom, saying that while the company's strategy will push it in a favorable direction, in the near term the primary catalyst appears to be the chance to recombine with CBS (CBS).
ED Consolidated Edison
$76.55

0.66 (0.87%)

01/12/18
JPMS
01/12/18
INITIATION
Target $78
JPMS
Underweight
Consolidated Edison initiated with an Underweight at JPMorgan
JPMorgan analyst Christopher Turnure started Consolidated Edison with an Underweight rating and $78 price target. The company's growth profile in 2019 is "mildly less visible" than large regulated peers due to the lack of a 2020 rate plan or rate base growth guidance and the impact of its renewables and midstream businesses, Turnure tells investors in a research note. He believes investors are paying a premium valuation for a company with average growth.
09/26/17
EVER
09/26/17
DOWNGRADE
EVER
Underperform
Consolidated Edison downgraded to Underperform from In Line at Evercore ISI
Evercore ISI analyst Greg Gordon downgraded Consolidated Edison to Underperform and maintained a $74 price target. The analyst believes regulated utilities look fully valued given interest rate implications and potential for tax reform and said Consolidated Edison has an unattractive total return profile.
02/02/18
UBSW
02/02/18
INITIATION
Target $80
UBSW
Neutral
Consolidated Edison initiated with a Neutral at UBS
UBS analyst Daniel Ford started Consolidated Edison with a Neutral rating and $80 price target.
01/12/18
01/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mosaic (MOS) reinstated with a Neutral at JPMorgan. 2. Vantiv (VNTV) initiated with an Overweight at Stephens. 3. Copa Holdings (CPA) initiated with a Buy at BofA/Merrill. 4. Edison International (EIX) was initiated with a Neutral and Consolidated Edison (ED) was initiated with an Underweight at JPMorgan. 5. New Relic (NEWR) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ANET Arista Networks
$303.29

1.17 (0.39%)

02/14/18
PIPR
02/14/18
NO CHANGE
Target $230
PIPR
Neutral
Arista more likely to win 945 case after key win from appeals board, says Piper Jaffray
Piper Jaffray analyst James Fish notes that Arista Networks (ANET) received a "key win" in the 945 case against Cisco (CSCO), as the Federal Appeals Court found the 668 patent as un-patentable. This leaves less "ammo" for Cisco to win in the 945 case and increases the probability of an Arista win, he contends. The analyst believes this recent development was already expected to go in Arista's favor given the past few rulings as it related to the 668 patent. Fish reiterates a Neutral rating and $230 price target on Arista's shares.
02/07/18
GSCO
02/07/18
INITIATION
Target $320
GSCO
Conviction Buy
Arista Networks initiated with a Conviction Buy at Goldman Sachs
Goldman analyst Rod Hall initiated Arista Networks with a Conviction Buy and $320 price target. Hall said Arista's premium valuation is supported by strong secular growth in the greater than100G data center switching market combined with execution. The analyst differs with consensus on R&D intensity forecasting 2018 R&D/Sales of 16.4% versus consensus of 18.2%. This note corrects our previous note that said shares were initiated with a Buy rating.
02/06/18
GSCO
02/06/18
INITIATION
Target $320
GSCO
Buy
Arista Networks initiated with a Buy at Goldman Sachs
Goldman analyst Rod Hall initiated Arista Networks with a Buy and $320 price target. Hall said Arista's premium valuation is supported by strong secular growth in the greater than100G data center switching market combined with execution. The analyst differs with consensus on R&D intensity forecasting 2018 R&D/Sales of 16.4% versus consensus of 18.2%
02/13/18
RBCM
02/13/18
NO CHANGE
Target $310
RBCM
Outperform
Arista Networks price target raised to $310 from $234 at RBC Capital
RBC Capital analyst Mitch Steves raised his price target on Arista Networks (ANET) to $310, saying that the recent multiple expansion suggests that expectations are firming for a "notable beat and raise" on Q4 earnings. The analyst believes that operating margins will become a focal point for the company going forward, adding that the weakness in Juniper's (JNPR) quarter implies market share gains in the Data Center space. Steves also expects Arista competition with Cisco (CSCO) to tighten as the former takes up more market in Hyperscale while the latter protects is core enterprise business. The analyst keeps his Outperform rating on Arista Networks.
SSNC SS&C
$49.76

0.75 (1.53%)

01/17/18
BARD
01/17/18
DOWNGRADE
BARD
Neutral
DST Systems downgraded to Neutral from Outperform at Baird
Baird analyst David Koning downgraded DST Systems (DST) to Neutral following the company's agreement to be acquired by SS&C Technologies (SSNC).
01/16/18
WBLR
01/16/18
DOWNGRADE
WBLR
Market Perform
SS&C downgraded to Market Perform from Outperform at William Blair
William Blair analyst Christopher Shutler downgraded SS&C Technologies (SSNC) to Market Perform saying the risk/reward is more balanced following the rally in the shares post the DST Systems (DST) acquisition announcement.
01/12/18
EVER
01/12/18
DOWNGRADE
Target $83
EVER
In Line
DST Systems downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst David Togut downgraded DST Systems (DST) to In Line with an $83 price target following the company's agreement to be acquired by SS&C Technologies (SSNC).
01/12/18
DADA
01/12/18
DOWNGRADE
Target $84
DADA
Neutral
DST Systems downgraded to Neutral at DA Davidson on SS&C deal
As noted earlier, DA Davidson analyst Peter Heckmann downgraded DST Systems (DST) to Neutral from Buy and raised his price target to $84 from $72. Heckmann cites the company's acquisition by SS&C (SSNC) at $84 per share and believes that shareholder got a good outcome in the deal, estimating the probability of a competitive bid to be "quite low".
CGNX Cognex
$58.05

2.88 (5.22%)

01/19/18
DBAB
01/19/18
INITIATION
Target $80
DBAB
Buy
Cognex resumed with a Buy at Deutsche Bank
Deutsche Bank analyst Karen Lau resumed coverage of Cognex with a Buy rating and $80 price target. The analyst believes the company is favorably positioned as a focused play on the secular automation theme.
12/08/17
DAIW
12/08/17
UPGRADE
DAIW
Buy
Cognex upgraded to Buy from Outperform at Daiwa
11/08/17
JPMS
11/08/17
DOWNGRADE
Target $125
JPMS
Underweight
Cognex downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Paul Coster downgraded Cognex to Underweight with an unchanged price target of $125 citing valuation. The analyst recommends using the recent strength in the shares as a selling opportunity.
08/14/17
WOLF
08/14/17
UPGRADE
WOLF
Outperform
Cognex upgraded to Outperform from Peer Perform at Wolfe Research
LOGM LogMeln
$130.20

4.25 (3.37%)

12/19/17
JPMS
12/19/17
NO CHANGE
Target $145
JPMS
Overweight
LogMeln cash flow, capital return outlook warrants buying, says JPMorgan
JPMorgan analyst Sterling Auty notes LogMeIn stock reacted negatively on management's 2018 and 2020 outlook for revenue growth as expectations were elevated into the event. However, the analyst thinks this is "a knee-jerk reaction" to a number and not really the market seeing that the fundamentals are still moving in the right direction, given "solid" growth, expanding margins and capital return. Auty reiterates an Overweight rating and $145 price target on the shares.
12/20/17
PIPR
12/20/17
NO CHANGE
Target $150
PIPR
Overweight
LogMeln outlook not directly comparable to consensus, says Piper Jaffray
Piper Jaffray analyst Alex Zukin says that since LogMeln is no longer incorporating acquisitions into its outlook, yesterday's guidance is not perfectly comparable to consensus estimates. The analyst views both the 2018 outlook and three-year targets issued at yesterday's analyst day as conservative. He sees "significant valuation support" from free cash flow following yesterday's 3% pullback and keeps an Overweight rating on LogMeln. The analyst, however, lowered his price target for the shares to $150 from $183.
12/20/17
NEED
12/20/17
NO CHANGE
Target $130
NEED
Buy
LogMeln price target lowered to $130 at Needham after analyst day
After attending LogMeln's analyst day meeting, Needham analyst Richard Valera noted that the organic revenue growth targets put forward were below what he and the Street had been expecting and he cut his price target on the stock to $130 from $135. However, he said he suspects the targets "embed some of the company's historical conservatism" and noted that its EBITDA targets remain largely inline with prior expectations. Valera keeps a Buy rating on LogMeIn shares.
02/08/18
JPMS
02/08/18
NO CHANGE
JPMS
Overweight
LogMeln acquisition of Jive positive for shareholders, says JPMorgan
JPMorgan analyst Sterling Auty views LogMeln's (LOGM) acquisition of Jive Communications for $342M in cash as positive for both growth and shareholders. The deal will add needed top-line growth, bolster the overall platform, and capitalize on the "robust" unified communications as a service market, Auty tells investors in a research note. He sees LogMeln benefitting as competitors RingCentral (RNG) and 8x8, Inc. (EGHT) focus on moving into the large enterprise segment. The analyst keeps an Overweight rating on LogMeln.
FLS Flowserve
$42.72

0.53 (1.26%)

12/07/17
GSCO
12/07/17
DOWNGRADE
GSCO
Sell
Flowserve downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Joseph Ritchie downgraded Flowserve (FLS) to Sell citing concerns over free cash flow and his belief that consensus expectations are aggressive. The analyst tonight also upgraded Ingersoll-Rand (IR) to Buy and downgraded Johnson Controls (JCI) to Sell.
12/11/17
12/11/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kimberly-Clark (KMB) downgraded to Sell from Neutral at Citi with analyst Wendy Nicholson citing "stiff competition" Kimberly-Clark faces "in multiple categories in multiple markets." 2. TSYS (TSS) downgraded to Neutral from Buy at Goldman Sachs with analyst James Schneider citing valuation with the shares approaching his unchanged price target of $80. 3. Paccar (PCAR) downgraded to Neutral from Overweight at JPMorgan with analyst Ann Duignan saying the North American Class 8 truck market is likely to peak in 2018 and Paccar's stock is likely to continue to see multiple compression. 4. Flowserve (FLS) downgraded to Hold from Buy at Stifel with analyst Nathan Jones saying he sees no near-term catalysts given his expectation of orders being flat to down in the fourth quarter. 5. Brixmor (BRX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/17
STFL
12/11/17
DOWNGRADE
Target $43
STFL
Hold
Flowserve downgraded to Hold on lack of near-term catalysts at Stifel
As previously reported, Stifel analyst Nathan Jones downgraded Flowserve to Hold from Buy, saying he sees no near-term catalysts given his expectation of orders being flat to down in Q4. He also sees considerable uncertainty around the timing of margin recovery in its IPD segment. Jones maintains a $43 price target on Flowserve shares.
12/11/17
STFL
12/11/17
DOWNGRADE
STFL
Hold
Flowserve downgraded to Hold from Buy at Stifel
MULE MuleSoft
$26.02

0.5975 (2.35%)

01/23/18
NOMU
01/23/18
INITIATION
Target $30
NOMU
Buy
MuleSoft initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Eberle started MuleSoft with a Buy rating and $30 price target. The company's "revolutionary" Anypoint Platform is providing the core foundation for an organization's most important digital initiatives, the analyst tells investors in a research note. He believes the trend toward containers and microservices is a "significant tailwind" for MuleSoft.
01/23/18
NOMU
01/23/18
INITIATION
Target $30
NOMU
Buy
MuleSoft initiated with a Buy at Nomura Instinet
Nomura initiated MuleSoft with a Buy and $30 price target.
01/08/18
LEHM
01/08/18
UPGRADE
Target $29
LEHM
Overweight
MuleSoft upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Raimo Lenschow upgraded MuleSoft to Overweight and raised his price target for the shares to $29 from $28. The analyst views the current valuation as attractive given the company's "healthy" growth pipeline.
01/03/18
OPCO
01/03/18
NO CHANGE
Target $30
OPCO
Outperform
MuleSoft poised to benefit from several key growth drivers, says Oppenheimer
Oppenheimer analyst Ittai Kidron views MuleSoft as one of his top 2018 picks with the company poised to benefit this year from several key growth drivers, including incremental leverage from its expanded sales effort, pipeline expansion as new system integrator and channel partners are added, and the addition of new security and analytics capabilities to Anypoint. The analyst believes MuleSoft could potentially top 40% year over year growth in 2018. He reiterates an Outperform rating and $30 price target on the shares.
MDRX Allscripts
$14.45

0.29 (2.05%)

01/16/18
RHCO
01/16/18
DOWNGRADE
RHCO
Hold
Allscripts downgraded to Hold from Buy at SunTrust
01/16/18
RHCO
01/16/18
DOWNGRADE
Target $16
RHCO
Hold
Allscripts downgraded to Hold at SunTrust on valuation
As reported earlier, SunTrust analyst Sandy Draper downgraded Allscripts to Hold from Buy with a $16 price target. Draper says that while he is not changing his outlook on the company, the 43% run-up in the stock price in 2017 and PE multiple approaching a 2-year high warrants a rating change, as shares are now likely to be "fully valued". The analyst adds that 2018 may prove to be difficult for bookings relative to 2017, and that the Street consensus of FY18 EPS may be over-estimating cost-cutting.
01/29/18
CANT
01/29/18
NO CHANGE
Target $17
CANT
Overweight
Allscripts has good understanding of Practice Fusion investigation, says Cantor
Cantor Fitzgerald analyst Steven Halper notes a FierceHealthcare.com article last week suggested that an ongoing Department of Justice investigation had affected the purchase price paid by the company for Practice Fusion. Given the terms of the acquisition, Allscripts will inherit any potential liability that arises from the investigation, Halper tells investors in a research note. He believes, however, that Allscripts management has a good understanding of the issue and is comfortable with Practice Fusion's legal position. Allscripts can absorb any "reasonable monetary settlement if that is the outcome," Halper adds. He reiterates an Overweight rating on the shares with a $17 price target.
TRUE TrueCar
$11.25

0.275 (2.51%)

10/02/17
MSCO
10/02/17
UPGRADE
Target $13
MSCO
Equal Weight
TrueCar upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley analyst Brian Nowak upgraded TrueCar to Equal Weight from Underweight, as he believes the stock now trades at an appropriate valuation following the pullback after its Q2 results and guidance missed expectations. Nowak keeps a $13 price target on TrueCar shares.
10/11/17
GSCO
10/11/17
INITIATION
Target $17
GSCO
Neutral
TrueCar assumed with a Neutral at Goldman Sachs
Goldman analyst Christopher Merwin assumed coverage on TrueCar with a Neutral and $17 price target saying he would like to see traffic accelerate in order to become more positive on shares.
11/07/17
RBCM
11/07/17
NO CHANGE
Target $18
RBCM
Outperform
TrueCar price target lowered to $18 from $23 at RBC Capital
RBC Capital analyst Mark Mahaney lowered his price target on TrueCar to $18 following a Q3 revenue miss and a lower FY17 outlook. Mahaney says the company suffered from poor performance at its USAA channel, while operating expenditures also showed greater leverage than expected. The analyst keeps his Outperform rating, saying the company is working to address the USAA issues which were related to negative user traffic impact from its recently updated website. Mahaney adds that the company can benefit from the FY18 ramp of new products and initiatives.
11/07/17
JMPS
11/07/17
NO CHANGE
Target $19
JMPS
Outperform
TrueCar issue at USAA fixable, says JMP Securities
JMP Securities analyst Ronald Josey attributed TrueCar's Q3 revenue miss and Q4 revenue guidance shortfall to a change in the USAA car-buying experience driving a decline in cars sold. While USAA is a near-term headwind, Josey views the USAA issue as fixable, he tells investors in a post-earnings research note. Josey lowered his price target on TrueCar shares to $19 from $23 but keeps an Outperform rating on the stock, citing the upcoming catalysts of OEM incentives and TrueTrade.

TODAY'S FREE FLY STORIES

MU

Micron

$34.45

0.56 (1.65%)

16:04
12/18/18
12/18
16:04
12/18/18
16:04
Earnings
Micron CEO bullish on memory, storage industry growth trends »

"Micron reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 08

    Jan

AIR

AAR Corp.

$42.46

2.71 (6.82%)

16:04
12/18/18
12/18
16:04
12/18/18
16:04
Earnings
AAR reports Q2 adjuted EPS 39c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FDX

FedEx

$185.38

3.18 (1.75%)

16:04
12/18/18
12/18
16:04
12/18/18
16:04
Earnings
FedEx reports Q2 adjusted EPS $4.03, consensus $3.94 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CTIC

CTI BioPharma

$1.23

(0.00%)

16:03
12/18/18
12/18
16:03
12/18/18
16:03
Hot Stocks
CTI BioPharma receives input from FDA on pacritinib development »

CTI BioPharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIR

AAR Corp.

$42.46

2.71 (6.82%)

16:03
12/18/18
12/18
16:03
12/18/18
16:03
Earnings
Correction: AAR reports Q2 adjuted EPS 39c, consensus 57c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

MU

Micron

$34.47

0.58 (1.71%)

16:03
12/18/18
12/18
16:03
12/18/18
16:03
Earnings
Micron reports Q1 EPS $2.97, consensus $2.96 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 08

    Jan

GSAT

Globalstar

$0.36

0.0131 (3.74%)

16:02
12/18/18
12/18
16:02
12/18/18
16:02
Syndicate
Globalstar files to sell $60M in comon stock »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SURF

Surface Oncology

$7.18

-0.61 (-7.83%)

16:00
12/18/18
12/18
16:00
12/18/18
16:00
Hot Stocks
Breaking Hot Stocks news story on Surface Oncology »

Surface Oncology Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

15:58
12/18/18
12/18
15:58
12/18/18
15:58
Hot Stocks
Nintendo: NPD says Switch fastest-selling game console of this generation »

Nintendo said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$59.53

-1.4 (-2.30%)

15:50
12/18/18
12/18
15:50
12/18/18
15:50
Options
Defensive option play in SPDR Energy Fund as shares falter to 52-week lows »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

C

Citi

$53.87

-0.35 (-0.65%)

15:47
12/18/18
12/18
15:47
12/18/18
15:47
Periodicals
Citi may take nearly $180M loss on loans to Asian hedge fund, Bloomberg says »

Citigroup could face…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 11

    Feb

  • 15

    Apr

  • 13

    Jul

IGT

International Game

$16.17

0.57 (3.65%)

15:45
12/18/18
12/18
15:45
12/18/18
15:45
Options
International Game call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 19

    Dec

AXGN

AxoGen

$20.38

-7.15 (-25.97%)

15:44
12/18/18
12/18
15:44
12/18/18
15:44
Hot Stocks
Cliffside says Seeking Alpha's AxoGen story doesn't meet editorial standards »

Cliffside Research said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$48.43

-0.35 (-0.72%)

, FOXA

21st Century Fox

$48.74

-0.26 (-0.53%)

15:42
12/18/18
12/18
15:42
12/18/18
15:42
Periodicals
Advertisers pull out of Tucker Carlson's show after immigrant remarks, AP says »

Certain advertisers are…

FOX

21st Century Fox

$48.43

-0.35 (-0.72%)

FOXA

21st Century Fox

$48.74

-0.26 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBER

Uber

$0.00

(0.00%)

15:42
12/18/18
12/18
15:42
12/18/18
15:42
Periodicals
Uber asks for Chinese tariff exclusion amid e-bike ramp, Bloomberg says »

Ride-hailing giant Uber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$68.88

-1.79 (-2.53%)

, AET

Aetna

$0.00

(0.00%)

15:36
12/18/18
12/18
15:36
12/18/18
15:36
Periodicals
Judge defers ruling on keeping CVS, Aetna separate, Bloomberg reports »

U.S. District Judge…

CVS

CVS Health

$68.88

-1.79 (-2.53%)

AET

Aetna

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SCS

Steelcase

$14.21

0.04 (0.28%)

15:34
12/18/18
12/18
15:34
12/18/18
15:34
Options
Steelcase options imply 15.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

GD

General Dynamics

$162.31

-1.12 (-0.69%)

15:32
12/18/18
12/18
15:32
12/18/18
15:32
Hot Stocks
General Dynamics announces awarded of $335M U.S. Army contract »

The U.S. Army has awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

15:30
12/18/18
12/18
15:30
12/18/18
15:30
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

BIIB

Biogen

$291.73

-21.49 (-6.86%)

, MYL

Mylan

$28.72

-0.13 (-0.45%)

15:29
12/18/18
12/18
15:29
12/18/18
15:29
On The Fly
Street Fight: Analysts differ on Biogen as Tecfidera concerns send shares lower »

Shares of Biogen (BIIB)…

BIIB

Biogen

$291.73

-21.49 (-6.86%)

MYL

Mylan

$28.72

-0.13 (-0.45%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 24

    Dec

  • 18

    Mar

TACT

Transact Technologies

$8.46

-0.22 (-2.53%)

15:26
12/18/18
12/18
15:26
12/18/18
15:26
Hot Stocks
Grand Slam reports 7% stake in Transact, sends letter to board »

The letter said in part :…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:25
12/18/18
12/18
15:25
12/18/18
15:25
Conference/Events
Guggenheim CIO fixed income to hold an analyst/industry conference call »

Chief Investment…

AMC

AMC Entertainment

$13.89

-0.17 (-1.21%)

15:22
12/18/18
12/18
15:22
12/18/18
15:22
Conference/Events
AMC Entertainment management to meet with Wedbush »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFE

Pfizer

$42.14

-0.97 (-2.25%)

15:20
12/18/18
12/18
15:20
12/18/18
15:20
Options
Upside call buyers in Pfizer weekly contracts »

Upside call buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 05

    Jan

  • 29

    Jan

JBL

Jabil

$22.08

0.52 (2.41%)

15:19
12/18/18
12/18
15:19
12/18/18
15:19
Options
Jabil Circuit options imply 11.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.